Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics

Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung cancer. Irinotecan therapy is characterized by several dose-limiting toxicities and large interindividual pharmacokineti...

Descripción completa

Detalles Bibliográficos
Autores principales: de Man, Femke M., Goey, Andrew K. L., van Schaik, Ron H. N., Mathijssen, Ron H. J., Bins, Sander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132501/
https://www.ncbi.nlm.nih.gov/pubmed/29520731
http://dx.doi.org/10.1007/s40262-018-0644-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132501/
https://www.ncbi.nlm.nih.gov/pubmed/29520731
http://dx.doi.org/10.1007/s40262-018-0644-7

Ejemplares similares